Figures & data
Figure 1. Pseudo-ternary phase diagram showing concentration of lipid and surfactant of nanoemulsion formation.
Table 1. Optimization parameter for drug-loaded NLC.
Figure 2. DSC scan of (a) Compritol ATO 888; (b) drug; (c) physical mixture; (d) drug-loaded NLC.
Table 2. Optimized formula of 5-ALA NLC.
Figure 3. In vitro release of drug from NLC1B and drug solution at pH 5.
Figure 4. Permeation study of 5-ALA-loaded NLC in PBS at pH 5.
Figure 5. The effect of NLC over aqueous control on cell viability at different concentrations.
Figure 6. (a) z-axis image of control-treated irradiated group (b): z-axis image of NLC-treated irradiated group (c) z-axis image of NLC-treated nonirradiated group.
Figure 7. (a) CLSM image of control-treated irradiated group (b) CLSM image of NLC-treated nonirradiated group (c) CLSM image of NLC-treated irradiated group.
Table 3. Results of in vivo studies.
Figure 8. Role of NLC in enhancing PDT efficacy of 5-ALA.
